IMAGION BIOSYSTEMS LIMITED

IMAGION BIOSYSTEMS LIMITED (ASX: IBX)

Imagion Biosystems has achieved its enrolment target for the MagSense® HER2 imaging agent Phase 1 study and plans to close the study by 31st July.
The positive results from the Phase 1 study indicate potential clinical utility and support further development as an MRI imaging agent for detecting cancer.
The company will use the data for an Investigational New Drug (IND) application and plans to proceed with a multi-site Phase 2 study in the U.S.

2023-06-21 08:27:00

Imagion Biosystems appoints Isaac Bright, MD as CEO, effective 20 June 2023.
Dr. Bright brings over 20 years of experience in health industry and oncology-based molecular diagnostics.
His track record in strategic partnering, financing, and M&A will support Imagion's growth and vision.

2023-06-19 08:31:00

Imagion Biosystems Limited received approximately $412,903 from eligible shareholders for its non-renounceable entitlement offer, amounting to 24,288,420 shares.
The issue of new shares is expected on 21 April 2023, with trading to commence on 24 April 2023.
Approximately $1.97 million, representing 115,878,572 shares, remains as a shortfall, which the company has until 14 July 2023 to place at the board's discretion.

2023-04-19 08:23:00

Imagion Biosystems announced an entitlement offer to shareholders seeking to raise up to $2.4 million.
The Company secured a funding facility of up to $15 million with Mercer Street Global Opportunity Fund, LLC.
The funds will be used to prepare the Company’s MagSense® HER 2 breast cancer imaging agent for clinical development, fund pipeline growth into oncology indications and provide general working capital.

2023-03-07 09:13:00

Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by MRI.
Company now prioritising the development of its pipeline of tumour targeting MagSense® imaging agents for use with commercial MRI systems for faster path to patients and market.
Independent blinded review found that MagSense® HER2 imaging agent produces a change in image contrast and that contrast in nodes highly suspicious for tumour is distinctly different from MR image contrast seen in non-involved nodes.

2023-02-06 09:25:00